Replimune Group (REPL) Stock Highlights

12.49 | +4%

2024-12-21 04:47:40

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Statistics

Range Today

11.43 13.04

Volume Today 2.35M

Range 1 Year

4.92 17

Volume 1 Year 269.13M

Range 3 Year

4.92 30.89

Volume 3 Year 543.47M

Range 10 Year

4.92 54.85

Volume 10 Year 731.87M

Highlights

Market Capitalization 849.92M (small)

Floating Shares 43.76M

Current Price 12.49

Price To Earnings -3.65

Price To Book 1.99

Earnings Per Share -3.33

Payout Ratio 0%

Performance

Latest +4%

1 Month +14.27%

3 Months +11.82%

6 Months +62.42%

1 Year +65.65%

3 Years -51.65%

5 Years -14.57%

10 Years -21.94%

Benchmarks

Market Capitalization

0 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

0 / 368

Free Cashflow

0 / 352

Performance 5 years

0 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.